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Background: Oncolytic viruses, including vaccinia virus (VACV), are a promising alternative to classical mono-cancer
treatment methods such as surgery, chemo- or radiotherapy. However, combined therapeutic modalities may be
more effective than mono-therapies. In this study, we enhanced the effectiveness of oncolytic virotherapy by matrix
metalloproteinase (MMP-9)-mediated degradation of proteins of the tumoral extracellular matrix (ECM), leading to
increased viral distribution within the tumors.
Methods: For this study, the oncolytic vaccinia virus GLV-1h255, containing the mmp-9 gene, was constructed and
used to treat PC-3 tumor-bearing mice, achieving an intra-tumoral over-expression of MMP-9. The intra-tumoral
MMP-9 content was quantified by immunohistochemistry in tumor sections. Therapeutic efficacy of GLV-1h255 was
evaluated by monitoring tumor growth kinetics and intra-tumoral virus titers. Microenvironmental changes
mediated by the intra-tumoral MMP-9 over-expression were investigated by microscopic quantification of the
collagen IV content, the blood vessel density (BVD) and the analysis of lymph node metastasis formation.
Results: GLV-1h255-treatment of PC-3 tumors led to a significant over-expression of intra-tumoral MMP-9,
accompanied by a marked decrease in collagen IV content in infected tumor areas, when compared to
GLV-1h68-infected tumor areas. This led to considerably elevated virus titers in GLV-1h255 infected tumors, and to
enhanced tumor regression. The analysis of the BVD, as well as the lumbar and renal lymph node volumes,
revealed lower BVD and significantly smaller lymph nodes in both GLV-1h68- and GLV-1h255- injected mice
compared to those injected with PBS, indicating that MMP-9 over-expression does not alter the metastasis-reducing
effect of oncolytic VACV.
Conclusions: Taken together, these results indicate that a GLV-1h255-mediated intra-tumoral over-expression of
MMP-9 leads to a degradation of collagen IV, facilitating intra-tumoral viral dissemination, and resulting in
accelerated tumor regression. We propose that approaches which enhance the oncolytic effect by increasing the
intra-tumoral viral load, may be an effective way to improve therapeutic outcome.Background
Prostate cancer (PCa) is responsible for 11% of cancer-
related deaths in men in the US, second only to lung and
bronchial cancer cases [1]. In most patients, death is
caused by the formation of metastases. Therefore, the suc-
cess of therapy is strikingly dependent on the time point* Correspondence: aaszalay@genelux.com
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reproduction in any medium, provided the orof diagnosis [2], and the efficacy of the therapy. Com-
monly used classical cancer therapies still show deficits in
regard to their efficacy and/ or specificity. An exemplary
obstacle for successful treatment is the development of re-
sistance to chemo- or radiotherapy [3,4]. In the case of
surgery, malignant cells can remain after the primary
tumor is removed, which might lead to enhanced overall
survival, but not a complete recovery [5].
Therefore, it is necessary to investigate alternative
treatments. A promising therapeutic approach for the
treatment of PCa are oncolytic viruses such as vacciniaLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cessfully used in other malignancies such as pancreatic
tumors, squamous cell carcinoma, breast cancer or in
combination with a prodrug activated by the GLV-1h68-
carried marker gene β-galactosidase [7-10]. VACV repli-
cates exclusively in the cytoplasm [11] and has a large
genome well suited for inserts of up to 25 kb [12]. This
fact was exploited for the construction of further recom-
binant VACVs (rVACVs). The inserted genes can be
used to enhance therapeutic efficacy as in the case of a
GLAF-1 (a single chain antibody against vascular endo-
thelial growth factor (VEGF)) encoding VACV [13], or
to allow the use of imaging techniques such as positron
emission tomography (PET) [14,15].
In this study, the possibility to use oncolytic viruses as
a vector for the intra-tumoral expression of recombinant
proteins was explored to further enhance virotherapy by
elevating intra-tumoral titers, which may increase the
oncolytic effect. Generally, the extracellular matrix
(ECM) can be a hindrance for viral cell-to-cell spread-
ing, as reported for oncolytic adenoviruses, decreasing
the oncolytic effect. However, it was shown that the in-
sertion of the relaxin gene in adenoviruses leads to the
degradation of ECM components within the tumor
microenvironment, thus improving viral spreading
[16,17]. Further possible candidates, which can be used
for the intra-tumoral degradation of ECM components,
are the matrix-metalloproteinases (MMPs) [18]. MMPs
are zinc-dependent endopeptidases, usually expressed as
inactive zymogens. In their activated state, these MMPs
are important for the breakdown of several ECM pro-
teins, playing a role in various processes (e.g. tissue re-
modeling) and also in cancer progression [19,20]. In
addition, the cleavage of ECM proteins can result in the
shedding of ECM-bound growth factors, leading to mul-
tiple actions within the tumor microenvironment
[21,22]. For example, not only has an enhanced angio-
genesis been observed after MMP-mediated shedding of
pro-angiogenic factors (e.g. VEGF), but also a decreased
BVD due to anti-angiogenic factors (e.g. endostatin,
tumstatin, angiostatin) was reported [23-25].
In this study, the oncolytic VACV GLV-1h255, con-
taining the mmp-9 gene, was constructed to specifically
degrade the intra-tumoral ECM. Among the MMP-9
ECM substrates are collagen, laminin, fibrillin and
elastin [26]. Indeed, we could observe a significantly
decreased collagen IV content, accompanied by increased
intra-tumoral virus titers in GLV-1h255colonized PC-3
tumors. Additionally, the tumor regression process
started earlier in the treatment phase and was markedly
accelerated. Our results suggest that a virus-mediated
intra-tumoral degradation of ECM components offers
a new strategy to optimize oncolytic rVACV tumor
treatment.Methods
Cell culture
PC-3 (DSMZ no. ACC465) and A549 (ATCC no. CCL-
185) cells were cultured in RPMI 1640 supplemented
with 10% fetal bovine serum (FBS) and antibiotic solu-
tion (100 units/mL penicillin G and 100 units/mL
streptomycin) at 37°C and 5% CO2.
For CV-1 cells (provided by Genelux GmbH, Bernried)
DMEM instead of RPMI 1640 was used. Media and
additives were purchased from PAA (Pasching, Austria).
Construction of recombinant VACV GLV-1h255
The human MMP-9 cDNA clone was originally from
OriGene (Cat. SC116989), which encodes the Homo
sapiens matrix metallopeptidase 9 (Accession No.
NM_004994.2). The human MMP-9 cDNA was PCR
amplified with primers MMP9-5 [5’-GTCGAC(Sal I)
CACCATGAGCCTCTGGCAGCCC-3’] and MMP9-3
[5’-TTAATTAA(PacI) CTAGTCCTCAGGGCACTGCA-
3’] with the above mentioned clone as the template. The
PCR product was gel purified, and cloned into the pCR-
Blunt II-TOPO vector using the Zero Blunt TOPO PCR
Cloning Kit (Invitrogen). The resulting construct pCRII-
MMP9-1 was sequence confirmed. The MMP9 cDNA
was released from pCRII-MMP9-1 with Sal I and Pac I,
and subcloned into the TK transfer vector with the same
restriction sites, placing hMMP9 cDNA under the con-
trol of vaccinia early (SE) promotor. The resulting con-
struct TK-SE-hMMP9 was sequence confirmed.
TK-SE-hMMP9 was used to generate the recombinant
virus GLV-1h255, with GLV-1h68 as the parental virus,
replacing the p7.5-lacZ expression cassette and pSEL-
hTFR in the TK locus with the expression cassette of
hMMP-9.
MMP-9 protein analysis
PC-3 cells were infected with GLV-1h68 or GLV-1h255
at a multiplicity of infection (MOI) of 1. Supernatants
were collected 24 h post infection (p.i.) and sterile-filtred
(0.1 μm filter Schleicher & Schuell Dassel, Germany).
Cells were washed once with PBS and lysed by addition of
SDS sample buffer (130 mM Tris HCl pH 6.8, 4% (w/v)
SDS, 20% (v/v) glycerol, 5.3% (v/v) 2-mercaptoethanol,
0.15 mM bromphenol blue). Supernatants were mixed
(1:1) with SDS sample buffer. All samples were denatured,
separated by SDS-PAGE and transferred to nitrocellulose
membranes. MMP-9 was detected using a polyclonal anti-
MMP-9 antibody produced in goat (Neuromics, Edina
USA, GT15020) and a HRP-conjugated anti-goat antibody
(Sigma, Steinheim Germany, A8919). ECL solution
(90 mM p-coumaric acid, 250 mM luminol, 1 M Tris–
HCl, pH 8.5) was used as a substrate for the HRP reaction.
β-actin was detected using an anti-β-actin antibody pro-
duced in mouse (Abcam, Cambridge UK, ab6276) and a
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UK, ab6728).
For the zymography (Millipore, protocol MCPROTO
009, 2007), A549 cells were infected with GLV-1h68 or
GLV-1h255 at an MOI 0.1 for 24 h. At this time point
supernatants were collected and sterile-filtered. Cells
were washed once with PBS and lysed by addition of
non-reducing SDS sample buffer (w/o β-mercaptoetha-
nol). Supernatants were mixed (1:1) with non-reducing
SDS sample buffer. Protein samples were separated by
SDS-PAGE using 10% SDS gels containing 1 mg/mL gel-
atin. After separation the proteins were renatured and
developed for 1 d at 37°C. Gel staining was performed
with 0.5% (w/v) Coomassie Brilliant Blue.
Animal studies
PC-3 cells (2 × 106 in 100 μL PBS) were implanted sub-
cutaneously in the right abdominal flank of 6 – 8 week
old female nude mice (NCl:Hsd:Athymic Nude Foxn1nu,
Harlan Borchem, Germany). Tumors were measured
weekly in two dimensions using a digital caliper and
tumor volumes were calculated (length ×width2/2). After
approximately 3 weeks, a single dose of GLV-1h68 or
GLV-1h255 (5 × 106 plaque forming units (pfu) in 100
μL PBS) was injected into the tail vein (i.v.). Control ani-
mals were injected with 100 μL PBS. All animal experi-
ments were carried out in accordance with protocols
approved by the Regierung of Unterfranken (Würzburg,
Germany, protocol number AZ 55.2-2531.01-17/08)
and/ or the Institutional Animal Care and Use Commit-
tee (IACUC) of Explora BIOLABS, located in the San
Diego Science Center (San Diego, USA) (protocol num-
ber: EB08-003).
Viral titration in tumor samples
Tumors were snap-frozen in liquid nitrogen. After thaw-
ing tumors were weighed, cut into pieces using a scalpel
and transferred to M-tubes (Miltenyi Biotec, Bergisch
Gladbach, Germany) and mixed with the 2× volume of
buffer (1 tablet of Roche complete mini proteinase in-
hibitor dissolved in 50 mL of PBS). Homogenization of
tissues was done twice with a GentleMACS dissociator
(Miltenyi Biotec). Subsequently, samples underwent 3
freeze/thaw cycles and were sonified 3 times for 30 s
each time. Virus titers were obtained by performing a
standard plaque assay on CV-1 cells.
Virus replication assay
To analyze the in vitro growth kinetics of GLV-1h68 and
GLV-1h255, PC-3 cells were seeded in 24 well plates.
When the cell layer reached 90% confluency, cells were
infected with an MOI of 0.1 in triplicates for each time
point. At 1, 2, 4, 6, 10, 24, 48 and 72 hours post infec-
tion supernatants were obtained and cells were washedwith Hank’s BSS (PAA, Pasching, Austria). Cells were
detached using trypsin and pelleted by centrifugation
and resuspended in Hank’s BSS. All samples were snap
frozen in liquid nitrogen and stored at −80°C. To obtain
the viral titers, a standard plaque assay on CV-1 cells
was performed. Prior to the plaque assay, three freeze-
and-thaw cycles were completed to achieve a thorough
cell lysis.
Analysis of lumbar and renal lymph nodes
For the analysis of lymph node metastases in PC-3
tumor bearing mice, mice were sacrificed 24 days after
virus treatment as described above. To calculate the
volumes of lumbar and renal lymph node metastases,
the abdomen was opened and all organs were removed.
A picture of the now visible lymph nodes was taken,
using a ruler as a guide. The width and length were mea-
sured using Photoshop CS4 (Adobe Systems, Mountain
View, CA). Lymph node volumes were calculated using
the formula: length ×width2/2.
Histology, fluorescence microscopy and image analysis
100 μm tumor sections were prepared as described previ-
ously [27]. All of the following steps were carried out at
room temperature. Tissue sections were permeabilized
by incubation in PBS containing 0.2% Triton X-100 and
5% FBS (blocking solution) for 1 h. For fluorescence
labeling, sections were incubated for 12 h with the pri-
mary antibody in blocking solution. Subsequently, sec-
tions were washed with PBS and incubated with the
corresponding secondary antibody in blocking solution
for 4 h. Finally, tumor sections were washed in PBS and
mounted onto glass slides using Mowiol/DABCO.
The fluorescence labeled specimens were examined
using a stereo-fluorescence microscope (MZ16 FA,
Leica) equipped with a color CCD camera (DC500,
Leica). Images were acquired using the Leica IM1000 v
4.0 software and Photoshop CS4 was employed to adjust
levels and create overlays.
Collagen IV in PC-3 tumor sections was labeled with
an anti-collagen IV antibody (Abcam, Cambridge UK,
ab19808). Quantification was performed using ImageJ
(http://rsbweb.nih.gov/ij/). Three images (100x, Leica
MZ16 FA) from infected and three images from non-
infected areas were taken from each section. Images
taken from 3 non-consecutive sections for each tumor,
and 3 tumors per group were used for analysis.
MMP-9 expression was analyzed in PC-3 tumor sec-
tions labeled with MMP-9 antibody (Neuromics, Edina
USA, GT15020). Image acquisition was done as
described before, except that a magnification of 150x
was used (Leica MZ16 FA). Visualization of MMP-9 ex-
pression was also done with these sections. All images
were converted from RGB to grayscale for ImageJ
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sity measurements reported.
Analysis of blood vessel density
The blood vessel density was determined using micro-
scopic images (200x, Leica MZ16 FA) of CD31-labeled
(CD31 antibody, Millipore, mab1398Z) tumor sections.
Three non-consecutive sections from each tumor were
taken and 3 tumors per group were analyzed. For each
section, 3 images from infected and 3 from non-
infected areas were taken. Exposure time was adjusted
to ensure clear visibility of the blood vessels in each
section. Subsequently, 5 equidistant lines were drawn
in a template using Adobe Illustrator CS4. Each indi-
vidual image was superimposed with the template and
vessels crossing the lines were counted. The average
blood vessel density per section with standard devi-
ation is shown.
Statistical analysis
A two-tailed Student’s t test was used to determine
statistical significance (p values: * p < 0.05, ** p < 0.01,
*** p < 0.001). Error bars represent standard deviation.A
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MMP-9 is expressed in GLV-1h255 infected PC-3-cells and
shows enzymatic activity in vitro
In this study, the rVACV GLV-1h255 was constructed to
express human MMP-9 under control of the synthetic
early promoter as shown in (Figure 1A). The expression
of MMP-9 by GLV-1h255 infected PC-3 cells was con-
firmed by Western Blot (Figure 1B). To investigate en-
zymatic activity of secreted MMP-9 by zymography, we
infected A549 lung carcinoma cells with either GLV-
1h68 or GLV-1h255. In A549 cells, which are well suited
for protein over-expression, abundant protein expression
allowed the visualization of enzymatic activity of MMP-9
in both cell-lysates and the sterile-filtered supernatants
(Figure 1C).
MMP-9 is expressed in GLV-1h255 infected areas of PC-3
tumors
Expression of MMP-9 was also analyzed in PC-3 tumor
sections at 7 days p.i.. In PC-3 tumors from either PBS or
GLV-1h68 treated animals, an already high basal expres-
sion level of MMP-9 was detected, probably associated
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compared to tumors of both control groups (Figure 2A).
The over-expression of MMP-9 co-localized with GFP-
positive GLV-1h255-infected tumor areas. In addition,
the MMP-9 expression was significantly higher in
GLV-1h255 infected areas compared to non-infected
areas (Figure 2B). In comparison, MMP-9 expression in
GLV-1h68 infected areas was considerably lower than in
GLV-1h255 infected areas.
Virus-mediated MMP-9 expression enhances collagen IV
degradation in GLV-1h255 infected tumor areas
To analyze whether MMP-9 activity in GLV-1h255
infected tumors leads to the degradation of ECM com-
ponents, we investigated the distribution of collagen IV,
a protein of the ECM and substrate of MMP-9, inFigure 2 MMP-9 expression in PC-3 tumor sections and collagen IV q
using MMP-9 labeled PC-3 tumor sections. Nuclei (white) were stained with
were obtained at 7 days p.i. from PC-3 tumor-bearing mice injected with P
Quantification of MMP-9 expression was done by microscopic analysis. Mea
Quantification of collagen IV 7 days p.i. in GLV-1h68 or GLV-1h255 infected
magnification (Leica MZ16 FA) and converted from RGB to grayscale using
was 8/255.tumors. Indeed, in infected areas of GLV-1h255 infected
tumors, the collagen IV content was significantly lower
than in GLV-1h68 infected areas (Figure 2C). In general,
however, we observed a significantly higher collagen IV
content in GLV-1h68 infected tumors in comparison to
PBS treated tumors. This increase might be due to the
viral infection, leading to an uncontrolled inflammation
in the tumor microenvironment (reviewed in [28]),
which may result in a pronounced fibrotic deposition of
collagen. Therefore, virus-mediated MMP-9 expression
might minimize infection-related collagen IV fibrosis.
GLV-1h255 treatment of tumors accelerates the tumor
regression process by increasing intra-tumoral virus titers
To determine whether the virus-mediated expression of
MMP-9 and degradation of collagen IV may improveuantification. Intratumoral expression of MMP-9 (red) was visualized
Hoechst 33258 dye. GFP (green) is a VACV reporter gene. Tumors
BS, GLV-1h68 or GLV-1h255. All images are representative examples. (B)
n fluorescence intensities were measured with ImageJ. (C)
areas of PC-3 tumor sections. Images were taken at a 100×
Photoshop. For image analysis ImageJ was used, the threshold value
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Figure 4 Replication kinetics of GLV-1h68 and GLV-1h255 in
PC-3 cells. PC-3 cells were infected with GLV-1h68 and GLV-1h255
with an MOI of 0.1. Virus titers of infected PC-3 cells and their
supernatants were determined 1, 2, 4, 6, 10, 24, 48 and 72 hours
post infection by a standard plaque assay using CV-1 cells. Triplicates
of infected PC-3 cells were used for each time point.
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injected with a single dose of GLV-1h255. Control ani-
mals were injected with either GLV-1h68 or PBS. The
three phased growth pattern (growth, inhibition, regres-
sion) of PC-3 xenograft tumors after viral injection was
in accordance with previous observations [10]. Signifi-
cant tumor regression already occurred at 17 days p.i. in
GLV-1h255 treated animals, but not in those treated
with GLV-1h68. This indicates an enhanced oncolytic ef-
fect of GLV-1h255, compared to the parental GLV-1h68
virus. Furthermore, tumors of GLV-1h255 injected ani-
mals showed a significantly enhanced regression at
24 days p.i. when compared with PBS injected mice
(p < 0.001), whereas the difference in volumes between
GLV-1h68 and PBS treated tumors was also significant,
but to a lesser extend (p < 0.01) (Figure 3A).
Since the primary idea for the construction of GLV-
1h255 was to increase viral spreading and viral load in
infected tumors, enhancing the oncolytic effect, we ana-
lyzed virus titers in GLV-1h68 and GLV-1h255 infected
tumors at 7 days p.i. by plaque assay. Indeed, at this early
time point after infection, GLV-1h255 infected tumors
showed a significantly higher average virus titer than those
infected with GLV-1h68 (Figure 3B). To exclude the possi-
bility that the higher titers were due to a better replication
of GLV-1h255, in vitro replication in PC-3 cells was ana-
lyzed by a replication assay (Figure 4). In this case the rep-
lication of GLV-1h255 was not enhanced when compared
to the replication of GLV-1h68.
Over-expression of MMP-9 in GLV-1h255 infected tumors
does not lead to an enhanced angiogenesis
Angiogenesis is often linked to elevated expression levels
of MMP-9 as it influences the bioavailability of VEGFA B
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Figure 5 Analysis of lumbar and renal lymph node metastases in PC-3 tumor-bearing mice and of Here, the blood vessel density
should be mentioned first (Figure 5A, text labeled in yellow) and lymph nodes second (Figure 5B). (A) Blood vessel density in PC-3 tumor
sections, 7 days p.i.. For GLV-1h68 and GLV-1h255 blood vessels in infected (vv) and non-infected (ni) areas were counted. Infected areas were
determined by expression of the viral marker GFP. For each image (200x, Leica MZ16 FA) blood vessels crossing 5 equidistant lines were counted.
(B) Analysis of renal and lumbar lymph node enlargement. PC-3 tumor-bearing mice were injected i.v. with GLV-1h68, GLV-1h255 or PBS. The
mice were sacrificed 24 days p.i. and lymph nodes were measured (n = 6–7).
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effect on renal and lumbar lymph node metastases in
PC-3 tumor-bearing mice
PC-3 xenograft tumors have a high metastatic potential
in athymic nude mice [30-32] and the expression of
ECM-degrading enzymes might additionally increase the
shedding of tumor cells, resulting in elevated metastasis
formation. Of these metastases, the renal and lumbar
ones can be easily analyzed after a removal of organs
from the abdomen. To determine whether the intra-
tumoral expression of MMP-9 in GLV-1h255 treated
PC-3 tumors influence the metastatic spread, the volume
of renal and lumbar lymph nodes was measured
24 days p.i. (Figure 5B). The renal and lumbar lymph
nodes in GLV-1h255 injected mice had similar
volumes as in GLV-1h68 treated mice, and both were
significantly smaller than in PBS injected ones. There-
fore, the virus-mediated over-expression of MMP-9
enhances virotherapy of the primary tumor while sus-
taining the rVACV-metastasis reducing effect.Discussion
The use of oncolytic VACV is a promising approach for
the treatment of various types of cancer [7-10]. However,
the therapeutic efficacy relies extensively on the efficient
oncolysis of tumor cells [27], indicating that an efficient
viral spreading inside tumor mass is essential. In this
context, proteins of the ECM have been identified as an
obstacle for the intra-tumoral spreading of virus parti-
cles [33,34].Two recently published studies reported that
adenovirus-mediated intra-tumoral expression of relaxin
resulted in an increased tumor regression [16,17].
In the present study, we showed for the first time
that degradation of the tumoral ECM also enhanced
therapeutic efficacy of oncolytic rVACV. To achieve
tumoral ECM degradation, we used GLV-1h255 encod-
ing mmp-9, for the treatment of PC-3 tumor-bearing
mice.
PC-3 tumors of GLV-1h68 and PBS injected mice
showed a high basal MMP-9 expression. This might be
due to the presence of non-malignant stromal cells, e.g.
inflammatory cells such as neutrophils, macrophages or
lymphocytes, most of which express MMP-9 [22]. Since
PC-3 xenograft tumors have a high metastatic potential
[30-32] and the degradation of ECM proteins by MMP-9
may facilitate metastasis [21], we analyzed the size of
lumbar and renal lymph nodes in PC-3 tumor bearing
mice, as these have been shown to be colonized by
tumor cells, and increased in size compared to healthy
ones [6]. However, the GLV-1h255 mediated over-
expression of MMP-9 did not further enlarge these
lymph nodes, as they had a similar size compared to
GLV-1h68-treated animals and were significantly smaller
than those in PBS treated animals. In accordance,
Lavilla-Alonso et al. reported no increased tumor inva-
siveness by macrophage metalloelastase, another ECM
degrading enzyme, when administered in combination
with an oncolytic virus [35].
As MMP-9 can also induce angiogenesis by increasing
the bioavailability of VEGF [29] which may stimulate
primary tumor growth, we quantified the BVD in
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The infected areas of both GLV-1h68- and GLV-1h255
treated tumors revealed similar BVD, which was signifi-
cantly reduced compared to PBS-treated tumors.
Taken together, neither an increase in size of renal and
lumbar lymph nodes, nor an induction of angiogenesis
was observed in PC-3 tumor-bearing mice injected with
GLV-1h255. Therefore, the final biological function of
MMP-9 may strongly depend on the context and the
local microenvironment of MMP-9 over-expression.
In this study, we propose that the enhanced oncoly-
tic effect of GLV-1h255 could be due to the MMP-
9-mediated collagen IV degradation in PC-3 tumors.
Interestingly, the collagen IV content was significantly
increased in GLV-1h68 infected tumors compared to
PBS-treated tumors, which might be a result of an in-
flammatory reaction caused by viral infection. It has
already been reported that tumor-targeted microbes,
such as bacteria and viruses [27,36], induce an over-
whelming inflammatory reaction in the tumor micro-
environment, which is accompanied by an uncontrolled
collagen deposition. In normal wounded tissue, inflam-
mation is tightly controlled and ultimately leads to scar
formation and healing. Tumors however, which also
have been described by Dvorak as “wounds that do not
heal” [37], do not provide an orderly environment for
the resolution of an infection focus [28]. This may ex-
plain the excessive deposition of collagen IV in the con-
text of infection. The significantly decreased collagen IV
content in GLV-1h255 infected areas may be the reason
for the significantly higher virus-titer in GLV-1h255
infected tumors, compared to those infected with GLV-
1h68, due to an accelerated extracellular cell to cell
spreading. This would be in line with the findings of
Ganesh et al. and Kim et al., who reported an increased
tumor infection by adenoviruses after the degradation of
ECM proteins [16,17]. This may furthermore explain the
accelerated regression of GLV-1h255 infected tumors, as
higher titers could result in an increased oncolysis,
which has been shown to be an important factor for the
therapeutic efficacy of VACV [27].
Collectively, our study revealed that the degradation of
ECM within the tumor microenvironment can boost the
oncolytic effect of rVACV. Moreover, we showed here
that high levels of local, intra-tumoral ECM-degrading
enzymes can be produced by virus-infected tumor cells
themselves, certainly limiting systemic side effects.
Conclusions
In summary, the present study revealed that the deg-
radation of collagen IV (ECM) by VACV-encoded
MMP-9 may represent a new option to significantly en-
hance the oncolytic effect of rVACV in PC-3 xeno-
grafts. We confirmed that the degradation of collagenIV facilitated viral infection of the tumor tissue, repre-
sented by significantly higher viral tumor titers and an
accelerated tumor regression. Furthermore, both onco-
lytic viruses, parental GLV-1h68 and mmp-9-encoding
GLV-1h255, significantly reduced the size of lumbar
and renal lymph node metastases, indicating that
MMP-9 enhances both virotherapy of the primary
tumor and sustains the rVACV-metastasis reducing
effect.
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